Elraglusib by Actuate Therapeutics for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

Ligand agrees to acquire APEIRON Biologics for $100m

QARZIBA is indicated to treat high-risk neuroblastoma in patients aged 12 months and above. Credit: Kateryna Kon/Shutterstock. Ligand Pharmaceuticals has announced a definitive agreement for

July 9, 2024

Two NIAID grants will support research on impacts of climate change on HIV-related health outcomes

Two grants from the National Institute of Allergies and Infectious Diseases (NIAID), a four-year $3.2 million award and a 12-month $550,000 administrative supplement, will support

October 19, 2023

How a Baltimore neuroscience study is rewriting Black America’s relationship with medical research

Priscilla Agnew-Hines will never be able to forget that day in early 2020. On March 26, just weeks after Covid-19 officially became a global pandemic,

June 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.